Effect of anti-estrogens on the androgen receptor activity and cell proliferation in prostate cancer cells

Although some anti-estrogens have been reported to inhibit the proliferation of prostate cancer cells, few studies on the mechanism by which they suppress the growth of prostate cancer have been reported. We investigated, for the first time, whether anti-estrogens modulate the transactivation activity of the androgen receptor (AR) in prostate cancer cells. In DU-145 cells transfected with AR, the transactivation activity of AR was inhibited by tamoxifen and toremifene, even in the presence of 10 nM of DHT. On the other hand, in LNCaP cells having an endogenous AR mutation at codon 877, the activity of AR was suppressed by faslodex in the presence of 10 nM DHT, whereas it was not inhibited by tamoxifen nor toremifene. In PC-3 cells, both the cell growth and the AR activity were remarkably inhibited by tamoxifen at 50 μM. Faslodex and toremifene inhibited AR activity to some extent, but they seemed to function as agonists at higher concentrations. In PC-3 cells, the inhibition of cell growth by flutamide, faslodex and toremifene was much less than their suppression of AR activity. We also demonstrated that a synthetic estrogen diethylstilbestrol and progesterone-related drugs such as chlormadinone acetate and allylestrenol dose-dependently inhibited the activity of AR in DU-145 and PC-3 cells. These results highlight the anti-androgenic aspect of anti-estrogens and estrogens in regard to the AR-mediated transcription of the relevant genes in prostate cancer.

[1]  I. Leav,et al.  Comparative Studies of the Estrogen Receptors β and α and the Androgen Receptor in Normal Human Prostate Glands, Dysplasia, and in Primary and Metastatic Carcinoma , 2001 .

[2]  G. Prins,et al.  Estrogen receptor‐β: Implications for the prostate gland , 1999 .

[3]  H. Bonkhoff,et al.  Estrogen receptor expression in prostate cancer and premalignant prostatic lesions. , 1999, The American journal of pathology.

[4]  G. Prins,et al.  Estrogen receptor-beta: implications for the prostate gland. , 1999, The Prostate.

[5]  S. Steinberg,et al.  A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  O. Cussenot,et al.  Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. , 2001, Cancer research.

[7]  K. Pienta,et al.  A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. , 1998, Urology.

[8]  D. Lamb,et al.  Steroid Receptors in Prostate Cancer Development and Progression , 2000 .

[9]  J. Gustafsson,et al.  Frequent loss of estrogen receptor-beta expression in prostate cancer. , 2001, Cancer research.

[10]  S. Fosså,et al.  Prostate carcinoma expression of estrogen receptor-beta as detected by PPG5/10 antibody has positive association with primary Gleason grade and Gleason score. , 2002, Human pathology.

[11]  Hideo Araki,et al.  Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. , 2003, Cancer research.

[12]  L. Andersson,et al.  A role for estrogen receptor β in the regulation of growth of the ventral prostate , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[13]  E. Small,et al.  Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. , 1999, Cancer research.

[14]  F. Moretti,et al.  Signaling through estrogen receptors modulates telomerase activity in human prostate cancer. , 2002, The Journal of clinical investigation.

[15]  K. Griffiths.  Estrogens and prostatic disease , 2000 .

[16]  H. Huynh,et al.  Co-administration of finasteride and the pure anti-oestrogen ICI 182,780 act synergistically in modulating the IGF system in rat prostate. , 2001, The Journal of endocrinology.

[17]  M. Steiner,et al.  Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. , 2002, Cancer research.

[18]  R. Lathe,et al.  An endocrine pathway in the prostate, ERβ, AR, 5α-androstane-3β,17β-diol, and CYP7B1, regulates prostate growth , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[19]  G. Jenster,et al.  A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. , 1990, Biochemical and biophysical research communications.

[20]  E. Kyle,et al.  Prostate cancer cell growth inhibition by tamoxifen is associated with inhibition of protein kinase C and induction of p21waf1/cip1 , 1998, The Prostate.

[21]  Seong-Jin Kim,et al.  Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines. , 2002, Cancer research.

[22]  H. Bonkhoff,et al.  Differential expression of the estrogen receptor beta (ERβ) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma , 2003, The Prostate.

[23]  S. Ho,et al.  Expression of estrogen receptor (ER)-alpha and ER-beta in normal and malignant prostatic epithelial cells: regulation by methylation and involvement in growth regulation. , 2000, Cancer research.

[24]  J. Gustafsson,et al.  Cloning of a novel receptor expressed in rat prostate and ovary. , 1996, Proceedings of the National Academy of Sciences of the United States of America.